Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3B
pubmed:dateCreated
2001-8-10
pubmed:abstractText
Gene transfer vectors will dramatically increase the safety and effectiveness of cancer gene therapy, if they could restrict expression of the therapeutic products to the target tumors. To realize such a tumor-targeting system, telomerase is one of the most promising candidates. It is because telomerase activity is detected in the vast majority of tumors, but not in most normal cells. Activation of telomerase is tightly regulated at the transcriptional level of the telomerase catalytic subunit (hTERT). Therefore, the use of the hTERT promoter-driven vector system could restrict the expression of therapeutic products to telomerase-positive tumors. In this study, we constructed the expression vector of FADD gene with death domain afforded by the hTERT promoter (hTERT/FADD) and investigated its effect on tumors in vitro and in vivo. Transient transfection with the hTERT/FADD construct induced apoptosis in telomerase-positive tumor cells of wide range. In contrast, normal fibroblast cells without telomerase did not undergo apoptosis following the hTERT/FADD transfer. Furthermore, the growth of subcutaneous tumors in nude mice was significantly suppressed by the intratumoral injection of the hTERT/FADD construct (every day for one week) compared to the control (P<0.0005). The findings described here indicate the high potentiality of a novel telomerase-specific gene therapy of tumors with telomerase.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0250-7005
pubmed:author
pubmed:issnType
Print
pubmed:volume
21
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1937-43
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:11497281-Adaptor Proteins, Signal Transducing, pubmed-meshheading:11497281-Animals, pubmed-meshheading:11497281-Apoptosis, pubmed-meshheading:11497281-Carrier Proteins, pubmed-meshheading:11497281-DNA-Binding Proteins, pubmed-meshheading:11497281-Fas-Associated Death Domain Protein, pubmed-meshheading:11497281-Fibroblasts, pubmed-meshheading:11497281-Gene Therapy, pubmed-meshheading:11497281-Genetic Vectors, pubmed-meshheading:11497281-Humans, pubmed-meshheading:11497281-In Situ Nick-End Labeling, pubmed-meshheading:11497281-Luciferases, pubmed-meshheading:11497281-Mice, pubmed-meshheading:11497281-Mice, Nude, pubmed-meshheading:11497281-Plasmids, pubmed-meshheading:11497281-Promoter Regions, Genetic, pubmed-meshheading:11497281-Telomerase, pubmed-meshheading:11497281-Transcription, Genetic, pubmed-meshheading:11497281-Transfection, pubmed-meshheading:11497281-Tumor Cells, Cultured
pubmed:articleTitle
FADD gene therapy using the human telomerase catalytic subunit (hTERT) gene promoter to restrict induction of apoptosis to tumors in vitro and in vivo.
pubmed:affiliation
The Center for Surgery Research, The Cleveland Clinic Foundation, OH 44195, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't